Endothelial injury and thrombotic microangiopathy in COVID-19: Treatment with the lectin-pathway inhibitor narsoplimab

Alessandro Rambaldi; Giuseppe Gritti; Maria Caterina Micò; Marco Frigeni; Gianmaria Borleri; Anna Salvi; Francesco Landi; Chiara Pavoni; Aurelio Sonzogni; Andrea Gianatti; Francesca Binda; S. Fagiuoli; Fabiano Di Marco; Ferdinando Luca Lorini; Giuseppe Remuzzi; Steve Whitaker; Gregory Demopulos

doi:10.1016/j.imbio.2020.152001

Related publications

Article2003

[Mechanisms of endothelial damage in thrombotic microangiopathy].

María Piedad Ruiz‐Torres, F. Casighari, Marina Noris, Daniela Macconi, Miriam Galbusera, Giuseppe Remuzzi

Article1997

Pathogenesis and treatment of thrombotic microangiopathy.

Piero Ruggenenti, Jens Lutz, Giuseppe Remuzzi

Article2020

Immunity, endothelial injury and complement-induced coagulopathy in COVID-19

Luca Perico, Ariela Benigni, Federica Casiraghi, Lisa F. P. Ng, Laurent Rénia, Giuseppe Remuzzi

Article2023

Mutations in the alternative complement pathway in multiple myeloma patients with carfilzomib-induced thrombotic microangiopathy

Maria Moscvin, Christine‐Ivy Liacos, Tianzeng Chen, Foteini Theodorakakou, Despina Fotiou, Shahrier Hossain, Sean Rowell, Houry Leblebjian, Eileen Regan, Peter G. Czarnecki, Filippo Bagnoli, Niccolò Bolli, Paul G. Richardson, Helmut G. Rennke, Meletios A Dimopoulos, Efstathios Kastritis, Giada Bianchi

Article2021

Mutations in the Alternative Complement Pathway in Multiple Myeloma Patients with Carfilzomib-Induced Thrombotic Microangiopathy

Maria Moscvin, Christine‐Ivy Liacos, Tianzeng Chen, Foteini Theodorakakou, Despina Fotiou, Eileen Regan, Efstathios Kastritis, Meletios A Dimopoulos, Paul G. Richardson, Giada Bianchi